Clinical Trial Update: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating UB-VV111 with and without rapamycin for relapsed/refractory CD19+ B-cell malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rapamycin (sirolimus)
• UB-VV111

Snippet

Sponsor: Umoja Biopharma | Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin (NHL) | Phase 1 | Status: RECRUITING